Blackstone Life Sciences and Novartis launch Anthos Therapeutics to target high-risk cardiovascular diseases
In a strategic partnership aimed at advancing cardiovascular treatments, Blackstone Life Sciences has teamed up with Swiss pharmaceutical giant Novartis to create Anthos Therapeutics, a new biopharma company focused on developing innovative therapies for high-risk cardiovascular patients. With an initial capital infusion of $250 million, Blackstone Life Sciences will oversee the development and operational control of Anthos Therapeutics, which will be based in Cambridge, Massachusetts.
Groundbreaking Collaboration to Address Unmet Cardiovascular Needs
Blackstone Life Sciences’ investment platform will take a pivotal role in driving the development of Anthos’ products, with the company aiming to address the significant unmet medical need in the cardiovascular disease space. Nick Galakatos, Head of Blackstone Life Sciences and Chairman of Anthos, expressed excitement about the partnership, stating, “We are excited to collaborate with Novartis to create Anthos, with the goal of delivering important therapies for the high-risk cardiovascular patients who need them.” Galakatos highlighted Blackstone’s dedication to bringing essential medicines to market, often in collaboration with major biopharma companies to leverage both capital and scientific expertise.
Novartis Contributes Groundbreaking Antibody Treatment
In the deal, Novartis will contribute its cutting-edge antibody, MAA868, a key therapeutic agent designed to target Factor XI and Factor XIa – proteins central to the intrinsic coagulation pathway. MAA868 has the potential to prevent a wide range of cardiovascular disorders while minimizing or eliminating the risk of bleeding, offering an attractive alternative to traditional treatments. This long-acting therapy aims to provide significant advantages in treating conditions where bleeding risks have previously been a concern.
Jay Bradner, President of the Novartis Institutes for BioMedical Research, underscored the need for innovation in the cardiovascular disease space, commenting, “The need for new medicines to treat cardiovascular diseases is clear, and this agreement is part of our strategy to work with innovators outside our walls to advance medicines that have the potential to have a positive impact for patients.” Bradner also praised Blackstone Life Sciences for its proven expertise and strong leadership, noting that the team at Anthos Therapeutics is well-equipped to drive MAA868’s development to the next phase.
A Promising Future for Cardiovascular Treatments
The formation of Anthos Therapeutics marks a significant step forward in the pursuit of new cardiovascular therapies. With Blackstone Life Sciences taking the lead on development and Novartis contributing its cutting-edge science, this partnership has the potential to transform the landscape of high-risk cardiovascular care. Both companies are committed to addressing one of the most pressing needs in healthcare, with the goal of delivering treatments that could improve the lives of millions of patients around the world.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.